Atossa Therapeutics Inc (ATOS)

[glenn1919]

ATOS................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783

[Birdbrain Ideas]

There hasn't been a post on this board in six weeks. If these Stage 2 trials turn out well, this board will light up along with the share price.

[Laster]

I loved that wall at $1.04 yesterday. It was calling my name. I was too slow.
Then it was taken out. I wasn’t too upset because….
I was lucky enough for another wall at $1.05 that I helped take out. Then boom.
Chart looked good. News good. Repurchase plan news excellent.
What’s not to like.
Hope to see if move back above $2.
Good luck.

[tw0122]

Looking good. Hidden gem not any longer

[killrEngineer]

Wow. No comments?
10 million share repurchase announcement yesterday and study enrollment announcement today.

[DrJinx]

This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.

[Engle1488]

We are primed for a big run up people. In at 1.04

[Agreed]

The market cap is less than their holdings in cash...clearly undervalued.

[Agreed]

Insider buying by CEO and CFO, new patent protections...looking promising.

[DollarSquad]

Yes. You likely lost a lot of money. This investment is worthless. RMSL

[4MVault]

Did something just happen?

[slugo1]

Looking for bottom here

[ttottip]

Yes, very soon. This will reverse the trend.

[slugo1]

Soon

[ttottip]

Soon the 2.5's , 2.6's .....

[slugo1]

Yes

[ttottip]

The 2.6's on the horizon.

[slugo1]

That's one of the things I like about them Also there should be some updates coming

[ttottip]

140 millions of dollars cash? ATOS can do great things with this money.

[slugo1]

Nice buy worth alot when this hits $10.00

[ttottip]

Almost 36,000 shares buy at 2.49.

[DrHarleyboy]

Good Old "Blue Sky Breakout"././//./..//.///.././..////

[DrHarleyboy]

The Market is pulling it down with the broad sell-off. Will take some news like VSTM put out today to move up.

[benchman]

Down in pre-market, I guess not many people see it that way :-/

[DrHarleyboy]

Atossa Therapeutics Is A Takeover Target Worth Triple It's Current Stock Price

https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5640574-atossa-therapeutics-is-takeover-target-worth-triple-current-stock-price

[DrHarleyboy]

Big move coming, lots of buzz this weekend.

[powerwalker]

Press Release: Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
BY Dow Jones & Company, Inc.
— 5:22 PM ET 09/07/2021

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor

Atossa establishes intended criteria for non-use of additional shares for financing transactions

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
) , a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, has adjourned today's special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date.

The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date. While the votes cast to date have been strongly in favor of the proposal (73% of shares voted have been voted in favor), only 58% of the outstanding shares of common stock have been voted with 42% voting in favor of the proposal. Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote.

Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders vote in favor of the proposed increase in authorized shares.

The newly authorized shares of common stock are primarily intended to be used to complete and/or support acquisitions, collaborations, partnerships and licensing transactions. If the proposal is approved by the stockholders, Atossa does not intend to issue any of the newly authorized shares of common stock for the purpose of raising capital in the nine months following approval of the proposal at a price less than $10 per share.

Details of the proposal, the stockholder meeting, and additional information on how to vote your shares can be found in the proxy statement, available here: https://www.sec.gov/Archives/edgar/data/1488039/000143774921019134/atos20210809_ def14a.htm

Atossa stockholders may vote by calling [phone] Monday through Friday 9 a.m. to 9 p.m. Eastern Time.

About Atossa Therapeutics ( ATOS
Loading...
Loading...
)

Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements Disclaimer Statement

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in breast density, reduction of Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:

Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
)

Kyle Guse, CFO and General Counsel

Office: [phone]

[e-mail]

Investor Relations Contact:

Core IR

Office:[phone]

[e-mail]

Source: Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
)


Dow Jones Newswires
09-07-21 1722ET

[slugo1]

What meeting?

[DrHarleyboy]

This could go bigly up, or down after the the meeting!

[DrHarleyboy]

October 1st $3.50 calls looking good @ .68 me thinks!

[XenaLives]

Still looking for the "missing link" here...

[eb0783]

Yeah, mine is not so small.

[DollarSquad]

No

[Jdanger 2]

Yeah. Small bet

[ADVFN_abullman]

Anyone else still in here ?

[ADVFN_abullman]

Hi folks, cashed in 3,16 last week. Seems to be a good chance for a rebound to 3.50 first. Need some time but will recover, imo.

[Treehunned]

Good loading zone to make bank again.

[powerwalker]

Glad to see you here, Xena, and your work from last week.

Peace,
Powerwalker

[slugo1]

I get lucky sometimes lol

[Jdanger 2]

You called it

[slugo1]

Nice entry point

[ttottip]

It will bounce back hard!

[ttottip]

What great prices!

[XenaLives]

Yes, this needs to be discussed openly, and not just by ATOS stockholders.

[MuskVoice]

[the_aaardvark]

Why all this old news

[willlbone]

Head and shoulders goes down the drain.

[XenaLives]

Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early

SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces that based on substantially positive results achieved with the patients enrolled to date in its Australian open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery, Atossa has halted the study and is accelerating its Endoxifen program in the United States.

“It is a welcome event to halt an ongoing clinical trial because the results are so overwhelmingly positive,” commented Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “Data from the first six patients in our Australian Phase 2 window of opportunity study shows a 74% average reduction in Ki-67, which is a common measure of tumor cell activity, and that at the time of surgery all patients had Ki-67 levels lower than 25%, which is an important threshold to improve long-term survival as identified in studies by others. We believe that additional enrollment will not alter these positive results so we are terminating the study early. This saves at least a year on the development time line allowing us to accelerate clinical development in the Unites States. We look forward to reporting final data from all patients in the study and sharing our continued progress in the development of oral Endoxifen.”

The study enrolled seven newly-diagnosed patients with ER+ and human epidermal growth factor receptor 2 negative (HER2-) stage 1 or 2 invasive breast cancer, requiring mastectomy or lumpectomy. Patients received Atossa’s proprietary oral Endoxifen for at least 14 days from the time of diagnosis up to the day of surgery. The primary endpoint is to determine if the administration of oral Endoxifen reduces the tumor activity as measured by Ki-67. The secondary endpoints are safety and tolerability and assessment of the study drug on expression levels of both estrogen and progesterone receptors. The Phase 2 study was conducted on behalf of Atossa by Avance Clinical, a leading Australian CRO.

The American Cancer Society (ACS) estimates that in 2020, 276,480 women will be diagnosed with breast cancer in the U.S. Every two minutes an American woman is diagnosed with breast cancer and 42,170 die each year.

Atossa is evaluating a number of potential clinical benefits and potential indications for its oral Endoxifen in the window of opportunity setting. These may include avoidance of surgery in some patients, such as older and/or frail patients, allowing for breast conservation surgery, and use of Endoxifen in place of other neoadjuvant therapies such as chemotherapy, aromatase inhibitors and other endocrine therapies like tamoxifen.

https://atossatherapeutics.com/atossa-therapeutics-phase-2-endoxifen-breast-cancer-study-produces-substantially-positive-results-allowing-study-to-be-halted-early/

[XenaLives]

Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants

SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has received $21 million from the exercise of outstanding warrants. The warrants were issued in financings in December 2020 and January 2021.

“In the past 60 days, we have made great progress in adding substantial cash resources so that we can accelerate development of our COVID-19 and breast cancer therapies,” commented Kyle Guse, CFO and General Counsel. “We completed financings with gross proceeds of approximately $60 million and in the past week have added an additional $21 million to our balance sheet through the exercise of outstanding warrants. We look forward to the speed at which we can now advance our programs in 2021.”

https://atossatherapeutics.com/atossa-therapeutics-receives-21-million-from-recent-exercises-of-outstanding-warrants/

[XenaLives]

Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
March 11, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.




...
SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases today announced the FDA has issued a “Safe to Proceed” letter under their Expanded Access Pathway, permitting the use of Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief.

“Dr. Goff recently contacted Atossa with an interest in gaining access to our Endoxifen under the FDA’s expanded access, or compassionate use, program for one of her patients,” commented Steven Quay, M.D., Ph.D., Atossa’s President and CEO. “The patient has recurrent ovarian cancer and recently underwent functional molecular genomic testing, using 3D tumor organoid cultures grown in the laboratory from the patient’s tumor. The organoid testing revealed that the combination of Endoxifen and alpelisib produced an exceptional tumor response. We are gratified to be able to help this patient and are anxious to follow her response to this drug combination. If the drug combination shows promise in this patient, Atossa will consider doing additional clinical studies in patients with ovarian cancer.”

Under the FDA expanded access program, the use of Atossa's proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board (IRB) must be obtained prior to providing oral Endoxifen to this patient.

About FDA Expanded Access

Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. For more information about this process, please see the FDA website: FDA Expanded Use Website

https://www.globenewswire.com/news-release/2021/03/11/2191501/0/en/Atossa-Therapeutics-Announces-Receipt-of-FDA-Safe-to-Proceed-Letter-for-Treatment-of-an-Ovarian-Cancer-Patient-with-Oral-Endoxifen-Under-Expanded-Access-Pathway.html